|Bid||2.3300 x 1000|
|Ask||2.3400 x 300|
|Day's range||2.3100 - 2.4700|
|52-week range||0.1700 - 4.7400|
|PE ratio (TTM)||N/A|
|Earnings date||26 Feb 2018 - 2 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||17.50|
Encouraging Progression Free Survival and Evidence of Tumor Shrinkage Observed in Patients with Metastatic Pancreatic Cancer Resistant to Gemcitabine who had Failed on Multiple Prior Treatments Rexahn is Progressing Development of RX-3117 in Combination with Abraxane® in Newly Diagnosed Pancreatic Cancer Patients
NEW YORK, Jan. 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of REGENXBIO Inc. (NASDAQ:RGNX), Rexahn Pharmaceuticals, Inc. (NYSE:RNN), QuinStreet, Inc. (NASDAQ:QNST), NewMarket Corporation (NYSE:NEU), Stock Yards Bancorp, Inc. (NASDAQ:SYBT), and United States Lime & Minerals, Inc. (NASDAQ:USLM), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that Peter D. Suzdak, Ph.D., the Company’s Chief Executive Officer, will be presenting at the Annual Biotech Showcase™ 2018 conference. Dr. Suzdak is scheduled to present at 11:30 a.m. PST on Tuesday, January 9, 2018, in Franciscan - A (Ballroom Level) at the Hilton San Francisco Union Square, 333 O’Farrell St, San Francisco, CA. An audio webcast of the presentation will be available on the Company's website at www.rexahn.com in the Investor Relations section under 'Events and Presentations'.
ROCKVILLE, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced the appointment of Douglas J. Swirsky as its President and Chief Financial Officer, effective today.
The Rockville, Maryland-based company said it had a loss of 4 cents per share. Losses, adjusted for non-recurring gains, came to 15 cents per share. The results topped Wall Street expectations. The average ...